Research analyst, medium-term horizon, biotech, small-cap

Omni Bio Raises Cash, Wastes No Time Getting Back To Work

On April 24, 2014, Omni Bio Pharma (OTCPK:OMBP) entered into a $3 million private financing plan that secured $2 million as needed and $1 million in future funds from yet to be named sources. This is clearly good news for the company, as Omni Bio exited 2013 with only $485K in cash. Burn for the three months ended December 31, 2013 was $295K, and that was because the company was - for all intents and purposes - dark during that time. Burn for the two previous quarters averaged $450K. As such, we believe that cash as of March 31, 2014 was down to less than $200K.

The secured financing took place with Bohemian Investments, LLC, a Fort Collins,...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details